The FDA has given Sarepta Therapeutics the go-ahead to start a rolling submission for its Duchenne muscular dystrophy drug, eteplirsen. The green light comes 7 weeks after Sarepta parted company with its CEO Chris Garabedian–and his interim successor was quick to frame the regulatory breakthrough as the result of the subsequent shift in strategy.

…read more

Source: Sarepta surges after kicking off a rolling submission for its DMD drug


0 No comments